Towa International obtains the certification to commercialize in Libya

• This development allows the company to expand its presence in the North African market and facilitate access to essential drugs in Libya through its subsidiaries in Spain, Italy and Portugal.
• The Martorelles (Barcelona) plant will produce the medicines for Libya, with an annual capacity of 5.600 million doses and in the process of expansion.

Barcelona, October 16, 2024. Towa International, an international pharmaceutical holding company specializing in the research, development, manufacture, marketing and distribution of generic and value-added medicines, which distributes directly in Europe and the United States through its commercial subsidiaries, Towa Pharmaceutical and Breckenridge Pharmaceutical, and in more than 30 countries through its Towa2B business unit, has announced the formalization of a strategic agreement with Medica, one of Libya’s leading pharmaceutical companies. Through this agreement, which was signed during the CPhI World Congress, the company has received certification from the Pharmacy Department at the Ministry of Health of the State of Libya for the manufacture of non-sterile solid medicines and their distribution in the country, giving it access to the North African market for the first time.

This significant breakthrough will enable Towa International, through its network of subsidiaries in Spain, Italy and Portugal, to start exporting pharmaceutical products to Libya, improving patient access to essential medicines. The certification obtained is valid for five years, guaranteeing a stable, long-term cooperation framework with Medica.

João Paulo Nascimento, Chief Commercial Officer B2C Europe at Towa International, highlighted the relevance of the agreement for the company’s expansion in the North African region. “Our priority is to ensure that all patients in Libya have access to high-quality treatments. This certification not only reinforces our commitment to public health, but also opens up new commercial opportunities in a key market such as Libya.”

“With this agreement, Towa International takes another step forward in its internationalization process, reinforcing its position as a leader in the generics market “at Towa International we want to reach the largest number of patients in the world, as part of our ongoing commitment to internationalization” adds David Peix, CEO of Towa International.

Martorelles, the facility that will produce medicines for Libya

The Martorelles plant (Barcelona), one of the largest in Europe with more than 35,000 m², is responsible for producing medicines for the North African market. Its high production capacity, which will reach 5.600 million doses per year, continues to increase year after year.

These facilities, which already have the necessary certifications to export products to the European Union, the United States and Japan, have recently incorporated a new CMO/CDMO line and are in the process of expanding to include a new high containment area.